Amneal Pharmaceuticals, Inc.
AMRX
Classifica tra le azioni
#2966
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is... Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Prezzo delle azioni
$19.39
Capitalizzazione di mercato
$6.19B
Variazione (1 giorno)
1.09%
Variazione (1 anno)
95.46%
Paese
US
Scambia Amneal Pharmaceuticals, Inc. (AMRX)
Categoria
Healthcare
Utile per Amneal Pharmaceuticals, Inc. (AMRX)
Utile nel Jun 2026 TTM: $201.18M
Secondo gli ultimi rapporti finanziari di Amneal Pharmaceuticals, Inc., gli utili attuali della società sono $201.18M. Nel 2023, la società ha registrato un utile di $-40.27M, un aumento rispetto a agli utili del 2022, che erano di $-248.13M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Amneal Pharmaceuticals, Inc. dal 2014 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $201.18M | -465.69% |
| 2024 | $-55.01M | 36.61% |
| 2023 | $-40.27M | -83.77% |
| 2022 | $-248.13M | -891.07% |
| 2021 | $31.37M | -187.66% |
| 2020 | $-35.78M | -83.75% |
| 2019 | $-220.24M | 8.64% |
| 2018 | $-202.72M | -218.33% |
| 2017 | $171.32M | -20.25% |
| 2016 | $214.82M | 22.35% |
| 2015 | $175.58M | -2.09% |
| 2014 | $179.33M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 777.11% |
IN
|
